SINTX Technologies Achieves Patent Allowance for Antipathogenic Fibrous Materials in Infection-Prevention Market

SINTX Technologies receives patent allowance for silicon nitride materials, enhancing infection prevention capabilities in healthcare settings.

Quiver AI Summary

SINTX Technologies, Inc. has announced a significant development in the infection-prevention market, with the United States Patent and Trademark Office issuing a Notice of Allowance for its patent on "Antipathogenic Fibrous Materials." This patent secures extensive protection for SINTX's silicon nitride-based platform, which aims to neutralize pathogens in various applications, including medical devices and PPE. The company views this as a transformative milestone that could reduce healthcare-associated infections and expenses significantly, potentially saving billions and improving patient outcomes. With proven antimicrobial properties, SINTX plans to pursue partnerships to commercialize its technology, thereby expanding its presence in the estimated $30 billion global infection-prevention market.

Potential Positives

Issuance of a Notice of Allowance for a patent on "Antipathogenic Fibrous Materials," providing broad protection for SINTX's silicon nitride-based infection prevention platform.
The patent secures SINTX's position in the $30 billion global infection-prevention market, enhancing potential avenues for future growth and innovation across multiple healthcare sectors.
Leadership expresses optimism that the patent could significantly lower infection risks, reduce healthcare costs, and ultimately save lives, indicating transformative potential for patient care.
Commercialization strategies outlined, including partnerships and licensing agreements, suggest a rapid path to market adoption without the need for disruptive infrastructure changes.

Potential Negatives

Dependence on future clinical validation and market adoption poses a significant risk to the anticipated benefits of the newly allowed patent.
The press release emphasizes forward-looking statements, indicating potential volatility and uncertainty in future outcomes, which may negatively impact investor confidence.
Factors such as regulatory approvals and competition are noted as risks that could hinder SINTX's plans to capitalize on the patent, highlighting vulnerability in their business strategy.

FAQ

What is SINTX Technologies' recent patent allowance about?

SINTX Technologies received a Notice of Allowance for its patent on “Antipathogenic Fibrous Materials,” which secures protection for its silicon nitride-based infection prevention technology.

How does silicon nitride improve infection prevention?

Silicon nitride can actively neutralize pathogens at the point of contact, providing continuous, drug-free infection reduction in various healthcare settings.

Why is this patent significant for the healthcare industry?

The patent positions SINTX uniquely in the $30 billion infection-prevention market, with applications in medical devices, PPE, and healthcare infrastructure to reduce healthcare-associated infections.

What are the potential benefits of this technology for patients?

This technology could lower infection risks, reduce hospital stays, lower healthcare costs, and improve patient outcomes globally through enhanced infection control.

How does this patent affect SINTX's commercial strategy?

SINTX plans to pursue strategic partnerships and licensing agreements to accelerate product commercialization and expand its presence in the infection-prevention market.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$SINT Insider Trading Activity

$SINT insiders have traded $SINT stock on the open market 27 times in the past 6 months. Of those trades, 27 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $SINT stock by insiders over the last 6 months:

GREGG R. HONIGBLUM (Chief Investment Officer) has made 15 purchases buying 64,000 shares for an estimated $209,826 and 0 sales.
ERIC K. OLSON (President and CEO) has made 9 purchases buying 24,975 shares for an estimated $65,557 and 0 sales.
MARK LEWIS ANDERSON has made 2 purchases buying 15,000 shares for an estimated $44,800 and 0 sales.
JAY M MOYES purchased 3,000 shares for an estimated $10,756

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$SINT Analyst Ratings

Wall Street analysts have issued reports on $SINT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Ascendiant Capital issued a "Buy" rating on 05/30/2025

To track analyst ratings and price targets for $SINT, check out Quiver Quantitative's $SINT forecast page.

Full Release

Significant Development in the Estimated $30 Billion Global Infection-Prevention Market

SALT LAKE CITY, Utah, Sept. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance (PTOL-85) for its patent application titled, “ Antipathogenic Fibrous Materials.” The patent secures broad protection for SINTX’s proprietary silicon nitride–based antipathogen platform.

This allowance marks a significant intellectual property milestone for the Company, securing broad protection for the use of silicon nitride in multiple form factors designed to neutralize pathogens at the point of contact. The patent establishes a foundation for further infection-resistant innovation in medical devices, surgical care, wound management, filtration and PPE, and healthcare infrastructure – segments of a global infection-prevention market estimated to exceed $30 billion annually. This newly allowed patent positions SINTX as a unique participant across these verticals with a single enabling material.

Leadership Perspective
“We believe this is a defining moment for SINTX. This patent has the potential to elevate silicon nitride from a proven biomaterial into a true platform technology for infection prevention,” stated Eric K. Olson, Chairman, President & CEO of SINTX Technologies. “The protection we’ve secured will enable us to engineer silicon nitride into coatings, textiles, dressings, filters, and device surfaces—solutions that can lower infection risk, shorten hospital stays, reduce healthcare costs, and most importantly, save lives. We believe it is transformative for patients and a potential catalyst for long-term shareholder value.”

Why It Matters for Patients and the Healthcare System
Healthcare-associated infections (HAIs) remain one of the costliest and most persistent challenges in medicine. According to the CDC, 1 in 31 U.S. hospital patients has an HAI on any given day. Studies estimate tens of billions of dollars in annual direct costs, with per-case expenses ranging from ~$14,000 for catheter-associated UTIs to more than $48,000 for central line-associated bloodstream infections; surgical site infections average around $28,000 per case and can exceed $40,000.

By providing continuous, passive, drug-free pathogen inactivation, silicon nitride has the potential—pending clinical validation and adoption—to reduce infection incidence at scale. Even modest reductions could translate into billions in savings for hospitals and payers while improving outcomes globally.

Built on Decades of Peer-Reviewed Science
This milestone builds on more than a decade of evidence demonstrating silicon nitride’s antimicrobial and antibiofilm properties. Most recently, SINTX and academic collaborators reported that silicon nitride inactivated multiple lineages of SARS-CoV-2 and MERS-CoV coronaviruses during standardized in vitro plaque assays within minutes, achieving ~99.97% reduction at 10 minutes and complete inactivation by 30 minutes across multiple coronavirus lineages. When embedded into textiles, silicon nitride also demonstrated high levels of viral reduction.

“The allowed claims support what our data already show: silicon nitride can be engineered into surfaces of products that actively neutralize pathogens,” said Dr. Ryan Bock, Chief Technology Officer. “This important patent affords the Company to seek immediate opportunities in wound dressings, surgical drapes, and high-touch clinical environments, alongside longer-term applications in implant coatings and filtration media.”

Expanding a Robust IP Estate
This Notice of Allowance expands SINTX’s intellectual-property portfolio into a comprehensive antipathogen platform deployable across nearly every high-risk healthcare setting. It complements existing granted patents on antipathogenic face masks, systems for rapid viral inactivation, and advanced processing of silicon nitride ceramics for biomedical applications.

Commercialization Path and Market Impact
SINTX intends to pursue strategic partnerships, licensing agreements, and co-development programs with manufacturers of wound dressings, PPE, implant-adjacent components, filters, and healthcare infrastructure. The patent’s breadth of coverage, combined with silicon nitride’s manufacturing scalability and seamless integration into existing workflows, creates a rapid path to adoption without requiring disruptive infrastructure changes.

Looking Ahead
With this patent allowance, SINTX is positioned to accelerate product commercialization, expand its footprint in the estimated $30B+ infection-prevention market, and potentially enhance its long-term shareholder value.

“We fundamentally believe this patent may represent a paradigm shift for both patient care and our Company’s commercial trajectory,” Olson added. “It underscores the unique role SINTX can play in shaping the future of infection prevention worldwide with a biomaterial that matters.”

References
(Please see below references to sources above for scientific data, prevalence and cost contexts.)

For more information, visit www.sintx.com .

About SINTX Technologies, Inc.
Located in Salt Lake City, Utah, SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Through innovation and strategic partnerships, SINTX continues to expand its portfolio across multiple markets. For more information on SINTX Technologies or its materials platform, visit www.sintx.com .

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding: the potential benefits of the newly allowed patent, including the technology’s potential impact on infection prevention, patient outcomes, healthcare costs, and shareholder value; expectations for commercialization, market adoption, and strategic partnerships; and SINTX’s ability to expand its presence in the infection-prevention market. Forward-looking statements are based on current expectations, estimates, and projections about future events and involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such statements. Factors that could cause actual results to differ materially include, but are not limited to, risks related to regulatory approvals, manufacturing scale-up, market acceptance, competition, intellectual property protection, and other risks detailed in SINTX’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. SINTX disclaims any obligation to update these forward-looking statements, except as required by law.

Business and Media Inquiries for SINTX:
Elliot Sloane
ThroughCo Communications
[email protected]
917-291-0833

Katie Russo
ThroughCo Communications
[email protected]
501-282-5069

SINTX Technologies, Inc.
801.839.3502
[email protected]